Abstract

Immune cells must adapt to different environments during the course of an immune response. Here we study the adaptation of CD8+ T cells to the intestinal microenvironment and how this process shapes the establishment of the CD8+ T cell pool. CD8+ T cells progressively remodel their transcriptome and surface phenotype as they enter the gut wall, and downregulate expression of mitochondrial genes. Human and mouse intestinal CD8+ T cells have reduced mitochondrial mass, but maintain a viable energy balance to sustain their function. We find that the intestinal microenvironment is rich in prostaglandin E2 (PGE2), which drives mitochondrial depolarization in CD8+ T cells. Consequently, these cells engage autophagy to clear depolarized mitochondria, and enhance glutathione synthesis to scavenge reactive oxygen species (ROS) that result from mitochondrial depolarization. Impairing PGE2 sensing promotes CD8+ T cell accumulation in the gut, while tampering with autophagy and glutathione negatively impacts the T cell pool. Thus, a PGE2-autophagy-glutathione axis defines the metabolic adaptation of CD8+ T cells to the intestinal microenvironment, to ultimately influence the T cell pool.

CD8+ T cells reprogram their metabolism in response to the gut environment. Upon sensing of PGE2, gut CD8+ T cells reduce their mitochondrial content, an event that ultimately shapes the pool of CD8+ T cells in the intestinal tissue.

Details

Title
Prostaglandin E2 controls the metabolic adaptation of T cells to the intestinal microenvironment
Author
Villa, Matteo 1   VIAFID ORCID Logo  ; Sanin, David E. 2   VIAFID ORCID Logo  ; Apostolova, Petya 3   VIAFID ORCID Logo  ; Corrado, Mauro 4   VIAFID ORCID Logo  ; Kabat, Agnieszka M. 2 ; Cristinzio, Carmine 5 ; Regina, Annamaria 6   VIAFID ORCID Logo  ; Carrizo, Gustavo E. 7 ; Rana, Nisha 7 ; Stanczak, Michal A. 7   VIAFID ORCID Logo  ; Baixauli, Francesc 7   VIAFID ORCID Logo  ; Grzes, Katarzyna M. 7 ; Cupovic, Jovana 7 ; Solagna, Francesca 7   VIAFID ORCID Logo  ; Hackl, Alexandra 7 ; Globig, Anna-Maria 8   VIAFID ORCID Logo  ; Hässler, Fabian 7   VIAFID ORCID Logo  ; Puleston, Daniel J. 7 ; Kelly, Beth 7 ; Cabezas-Wallscheid, Nina 7   VIAFID ORCID Logo  ; Hasselblatt, Peter 8 ; Bengsch, Bertram 9   VIAFID ORCID Logo  ; Zeiser, Robert 10   VIAFID ORCID Logo  ; Sagar 8   VIAFID ORCID Logo  ; Buescher, Joerg M. 7   VIAFID ORCID Logo  ; Pearce, Edward J. 11 ; Pearce, Erika L. 12   VIAFID ORCID Logo 

 Max Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany (GRID:grid.429509.3) (ISNI:0000 0004 0491 4256); Medical University of Graz, Division of Rheumatology and Immunology, Department of Internal Medicine, Graz, Austria (GRID:grid.11598.34) (ISNI:0000 0000 8988 2476) 
 Max Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany (GRID:grid.429509.3) (ISNI:0000 0004 0491 4256); Johns Hopkins University School of Medicine, Bloomberg-Kimmel Institute of Immunotherapy, Department of Oncology, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311) 
 Max Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany (GRID:grid.429509.3) (ISNI:0000 0004 0491 4256); Johns Hopkins University School of Medicine, Bloomberg-Kimmel Institute of Immunotherapy, Department of Oncology, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); University Medical Center Freiburg, Department of Medicine I (Hematology and Oncology), Freiburg, Germany (GRID:grid.7708.8) (ISNI:0000 0000 9428 7911) 
 Max Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany (GRID:grid.429509.3) (ISNI:0000 0004 0491 4256); University of Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777); University of Cologne, Center for Molecular Medicine (CMMC), Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777); University of Cologne, Institute for Genetics, Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777) 
 Max Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany (GRID:grid.429509.3) (ISNI:0000 0004 0491 4256); University of Siena, Department of Medical Biotechnology, Siena, Italy (GRID:grid.9024.f) (ISNI:0000 0004 1757 4641) 
 Max Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany (GRID:grid.429509.3) (ISNI:0000 0004 0491 4256); University of Trieste, Department of Life Sciences, Trieste, Italy (GRID:grid.5133.4) (ISNI:0000 0001 1941 4308) 
 Max Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany (GRID:grid.429509.3) (ISNI:0000 0004 0491 4256) 
 University Medical Center Freiburg, Department of Medicine II, Freiburg, Germany (GRID:grid.7708.8) (ISNI:0000 0000 9428 7911) 
 University Medical Center Freiburg, Department of Medicine II, Freiburg, Germany (GRID:grid.7708.8) (ISNI:0000 0000 9428 7911); CIBSS Centre for Integrative Biological Signalling Studies, Freiburg, Germany (GRID:grid.517353.6) 
10  University Medical Center Freiburg, Department of Medicine I (Hematology and Oncology), Freiburg, Germany (GRID:grid.7708.8) (ISNI:0000 0000 9428 7911); CIBSS Centre for Integrative Biological Signalling Studies, Freiburg, Germany (GRID:grid.517353.6) 
11  Max Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany (GRID:grid.429509.3) (ISNI:0000 0004 0491 4256); Johns Hopkins University School of Medicine, Bloomberg-Kimmel Institute of Immunotherapy, Department of Oncology, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); CIBSS Centre for Integrative Biological Signalling Studies, Freiburg, Germany (GRID:grid.517353.6); University of Freiburg, Faculty of Biology, Freiburg, Germany (GRID:grid.5963.9) (ISNI:0000 0004 0491 7203); Johns Hopkins University, Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311) 
12  Max Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany (GRID:grid.429509.3) (ISNI:0000 0004 0491 4256); Johns Hopkins University School of Medicine, Bloomberg-Kimmel Institute of Immunotherapy, Department of Oncology, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); CIBSS Centre for Integrative Biological Signalling Studies, Freiburg, Germany (GRID:grid.517353.6); Johns Hopkins University, Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311) 
Pages
451
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2912902326
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.